The Association of the British Pharmaceutical Industry (ABPI) has welcomed NHS England’s new publication summarising the recent regional workshops held on biosimilar medicines.
NHS England, the Association of the British Pharmaceutical Industry (ABPI) and the AHSN Network have joined forces to launch an ambitious new programme, connecting digital health innovators with pharmaceutical companies to explore new innovations that could help people living with diabetes.
The Court has today made a judgment on the use of Avastin to treat a condition called wet age-related macular degeneration (wet AMD).
The Association of the British Pharmaceutical Industry (ABPI) and the AHSN Network today announce a new, five-year partnership to accelerate the introduction and uptake of transformative biomedical innovations into the NHS.
The Migration Advisory Committee (MAC) has published a report on the impact of European migration and its recommendations for the UK’s post-Brexit work immigration system.
The ABPI has responded to BMJ research into compliance with reporting the results of clinical trials.
In a week where the Office of Health Economics (OHE) has published a report on the ten most important medicines over the life of the NHS, Dr Sheuli Porkess outlines how the pharmaceutical industry takes a substance from molecule to medicine and how the process requires persistance.
Elliot Dunster, Head of External Affairs at the ABPI, takes a closer look at the 'no deal' guidance published by Government.
The ABPI today welcomes the publication of technical notices issued by the Government and the letter from the Department of Health and Social Care on medicines supply contingency planning. This gives guidance to pharmaceutical companies as they prepare for Brexit.
Today sees the launch of a consultation on proposals to change the 2016 ABPI Code of Practice for the pharmaceutical industry.